Nephrol Dial Transplant (2001) 16: 2172-2175
© 2001 European Renal Association-European Dialysis and Transplant Association
Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin E
1 Servicio de Nefrologia, 2 Servicio de Bioquímica and 3 Servicio de Hematologia, Hospital Universitari ‘Germans Trias i Pujol’, Badalona, Spain
Background. Cardiovascular diseases are the leading cause of death in haemodialysis patients. Hyperhomocysteinaemia is an independent risk factor. Basic research has provided strong evidence that oxidation of low-density lipoprotein (LDL) plays an important role in the pathogenesis of atherosclerosis. Oxidative stress, lipid metabolism alterations, and hyperhomocysteinaemia observed in haemodialysis patients could induce increases in LDL oxidation. This study was designed to determine the effect of folinic acid on hyperhomocysteinaemia and to assess the antioxidant efficacy of folinic acid. The antioxidant effect of folinic acid was compared with that of vitamin E.
Methods. Sixteen stable patients (11 men, five women; mean age 54.3±6.32 years) on standard haemodialysis received 400 mg of vitamin E, orally, at the end of each haemodialysis session for 3 months. After a 1-month wash-out, they received 10 mg of folinic acid, intravenously, at the end of each haemodialysis session for an additional 3 months. Blood samples were drawn in the morning after an overnight fast and before dialysis. Plasma vitamin E was analysed by high-pressure liquid chromatography. Malondialdehyde (MDA) was determined using a fluorimetric method and plasma copper oxidized anti-LDL antibodies (Ab-LDLox) were measured with an ELISA method using native LDL and oxLDL as antigens. Plasma homocysteine was determined by an FPIA method.
Results. Folinic acid supplements significantly reduced hyperhomocysteinaemia (-44%), MDA concentrations (-40%), and IgG-LDLox titres (-13%).
Conclusions. Treatment with folinic acid lowers plasma homocysteine levels and, like vitamin E, affords antioxidant protection, which prevents lipid peroxidation. This lowering of lipid peroxidation may reduce the risk of atherosclerosis and prevent or delay cardiovascular complications in HD patients.
Keywords: folinic acid; haemodialysis; homocysteine; lipid peroxidation
Correspondence and offprint requests to: Ramon Romero, Department of Nephrology, Hospital Universitari ‘Germans Trias i Pujol’, Carretera del Canyet s/n., E-08916 Badalona, Spain. Email: bbayes{at}teleline.es
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Vanholder, N. Meert, E. Schepers, G. Glorieux, A. Argiles, P. Brunet, G. Cohen, T. Drueke, H. Mischak, G. Spasovski, et al. Review on uraemic solutes II Variability in reported concentrations: causes and consequences Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3115 - 3121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bayes, M. C. Pastor, J. Bonal, A. Foraster, and R. Romero Oxidative stress, inflammation and cardiovascular mortality in haemodialysis--role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up Nephrol. Dial. Transplant., April 1, 2006; 21(4): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Durga, L. J. H. van Tits, E. G. Schouten, F. J. Kok, and P. Verhoef Effect of Lowering of Homocysteine Levels on Inflammatory Markers: A Randomized Controlled Trial Arch Intern Med, June 27, 2005; 165(12): 1388 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bayes, M. C. Pastor, J. Bonal, J. Junca, J. M. Hernandez, N. Riutort, A. Foraster, and R. Romero Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients Nephrol. Dial. Transplant., January 1, 2003; 18(1): 106 - 112. [Abstract] [Full Text] [PDF]
|
|